References
- Bresnahan JF, Vlietstra RE. Digitalis glycosides. Mayo Clin Proc 1979: 54(10): 675–84
- McGoon MD, Vlietstra RE, Holmes DR Jr, et al. The clinical use of verapamil. Mayo Clin Proc 1982: 57(8): 495–510
- Nies AS, Shand DG. Clinical pharmacology of propranolol. Circulation 1975: 52(1): 6–15
- Koch-Weser J. Metoprolol. N Engl J Med 1979: 301(13): 698–703
- Frishman WH. Nadolol: a new beta-adrenoceptor antagonist. N Engl J Med 1981: 305(12): 678–82
- Frishman WH. Atenolol and timolol, two new systemic beta-adrenoceptor antagonists. N Engl J Med 1982: 306(24): 1456–62
- Frishman WH. Pindolol: a new beta-adrenoceptor antagonist with partial agonist activity. N Engl J Med 1983: 308(16): 940–4
- Vlietstra RE. Pharmacokinetics of cardiovascular drugs. cardiovasc Clin 1980: 10(3): 255–70
- Parker JO, Porter A, Parker JD. Propranolol in angina pectoris: comparison of long-acting and standard-formulation propranolol. Circulation 1982: 65(7): 1351–5
- Frishman WH, Teicher M. New therapy update: long-acting propranolol. Cardiovasc Rev Rep 1983: 4(8): 1100–2
- Sum CY, Yacobi A, Kartzinel R, et al. Kinetics of esmolol. an ultra-short-acting beta blocker, and of its major metabolite. Clin Pharmacol Ther 1983: 34(4): 427–34
- Byrd RC, sung RJ, Marks J, et al. Safety and efficacy of esmolol (ASL-8052: an ultrashort-acting beta-adrenergic blocking agent) for control of ventricular rate in supraventricular tachycardias. J Am Coll cardiol 1984: 3(2 Pt 1): 394–9